



COMMUNICATION OF PRIVILEGED INFORMATION

20 November 2023

In accordance with the provisions of article 226 of the consolidated text of the Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, and other concordant provisions, ATRYS HEALTH, S.A. ("**ATRY'S**" or the "**Company**") hereby notifies:

Organic Guidance Update for the financial year 2023:

Following the communication of Privileged Information "*Binding Offer for 75.01% of Professional Group Conversia, S.L. ("**Conversia**")*" (registry number: 2039) and the communication of Other Relevant Information "*Notice of the Extraordinary General Shareholders' Meeting of December 2023*" (registry number: 25464) whereby a delegation in favour of the Board of Directors to issue convertible bonds for a maximum amount of up to 25 million euros will be submitted for the approval of the Extraordinary General Shareholders' Meeting of the Company:

The Company announces that once the sale of 75.01% of Conversia's share capital and the intended issuance of a contingent convertible bond (this instrument will not count as debt for the purpose of calculating the financial covenant ratios of the syndicated financing) will be executed, a total of 43 million euros will be used before 31/12/2023 to repay the Group's financial debt, with an estimated Net Financial Debt / Adjusted EBITDA ratio of 3.5x. The debt repayment will result in annual savings of 3.85 million euros in the Group's financial expenses as a result of: (i) the reduction of the loan principal; (ii) the decrease in the floating interest rate as the "Net Financial Debt / Adjusted EBITDA" ratio will be below 4x.

As a consequence of the projected sale of the 75.01% of Conversia, the Company updated its organic Guidance ("excluding acquisitions and sale of assets") for the year 2023:

Guidance communicated on 22 March 2023 (see: "[OIR FY 2023 Earnings Preview](#)"):

<u>Guidance 22/03/2023</u>	<u>Proforma 2022</u>		<u>Guidance 2023</u>	<u>(%)</u>
Revenues	210,9 MEUR	→	232-238 MEUR	10-13%
Adj. EBITDA %	47,2 MEUR 22,4%	→	52-53 MEUR 22,2%	10-13%

Guidance updated as of 20 November 2023:

<u>Updated Guidance</u>	<u>Proforma 2022⁽¹⁾</u>		<u>Guidance 2023⁽¹⁾</u>	<u>(%)</u>
Revenues	182,2 MEUR	→	202-208 MEUR	10-14%
Adj. EBITDA %	40,7 MEUR 22,1%	→	45-46 MEUR 22,2%	10-13%

⁽¹⁾ It does not include Atrys Switzerland and Conversia on proforma 2022 & Guidance 2023

Ms Isabel Lozano Fernández

Chief Executive Officer